Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2026-06-05 M&A Activity
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Updates
M&A Activity Classification · 88% confidence The document is an official stock exchange filing under SEBI LODR Regulation 30 providing an update that the NCLT sanctioned the Scheme of Amalgamation between two companies. It is not the full merger proxy or detailed plan (so not MA in the US‐SEC sense) nor a simple regulatory certification or dividend notice. It is a public announcement of a corporate merger transaction under Indian continuous disclosure rules, fitting the M&A Activity category (Code: TAR).
2026-06-05 English
In continuation to our earlier intimation dated March 18, 2026, with respect to merger petition, we would like to inform that Hon''ble National Company Law Tribunal ("NCLT") on June 05, ....
M&A Activity Classification · 85% confidence The document is an official stock exchange filing under SEBI Listing Regulations providing an update on the sanctioning of a Scheme of Amalgamation (merger) by the National Company Law Tribunal between Dhanuka Laboratories Limited and Orchid Pharma Limited. It is clearly an announcement of a merger/amalgamation rather than a general regulatory notice or report publication. Therefore, it falls under M&A Activity (Code: TAR).
2026-06-05 English
Transcript of Analysts/ Investor Earning Call held on May 26, 2026 for the Quarter and Financial Year ended on March 31, 2026
Call Transcript Classification · 95% confidence The document is an official submission under SEBI regulations containing the full text transcript of the Q4 FY ’26 earnings conference call held on May 26, 2026, including management remarks and Q&A. This matches the definition of a Call Transcript (CT).
2026-06-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is titled “Transcript of Analysts/ Investors Earning Call held with Public at large on May 26, 2026” and contains the full text of an earnings conference call, including moderator introductions, prepared remarks by management, and Q&A. It clearly matches the definition of a call transcript (CT).
2026-06-01 English
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026.
Audit Report / Information Classification · 85% confidence The document is titled “Annual Secretarial Compliance Report” prepared by an external firm of practising company secretaries and filed under Regulation 24A of SEBI’s Listing Obligations. It contains detailed audit-style tables, observations on statutory compliance and is a standalone compliance/audit report rather than a company Annual Report, earnings release or simple announcement. There is no financial statement data as in an interim or annual report, nor is it a brief notice. It best matches the “Audit Report / Information” category (AR). FY 2026
2026-05-30 English
Investor / Analysts call recording for the Quarter- 4 and Financial year ending March 31, 2026.
Regulatory Filings Classification · 87% confidence The document is an exchange filing under SEBI LODR Regulation 30 informing the exchanges and public about the availability of the audio recording of the Analysts/Investors Earnings Call via a link. It does not contain financial data or the call transcript itself but is a regulatory announcement required under listing rules. This falls into the general ‘Regulatory Filings’ category (RNS).
2026-05-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.